CA2838945A1 - Glioblastoma inhibiting compounds and their use - Google Patents

Glioblastoma inhibiting compounds and their use Download PDF

Info

Publication number
CA2838945A1
CA2838945A1 CA2838945A CA2838945A CA2838945A1 CA 2838945 A1 CA2838945 A1 CA 2838945A1 CA 2838945 A CA2838945 A CA 2838945A CA 2838945 A CA2838945 A CA 2838945A CA 2838945 A1 CA2838945 A1 CA 2838945A1
Authority
CA
Canada
Prior art keywords
glioblastoma
compound
cells
alterations
gene encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2838945A
Other languages
English (en)
French (fr)
Inventor
Bjorn Scheffler
Martin Glas
Matthias Simon
Sabine GOGOLOK
Daniel TRAGESER
Roman REINARTZ
Anja WIELAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Rheinische Friedrich Wilhelms Universitaet Bonn
Life and Brain GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rheinische Friedrich Wilhelms Universitaet Bonn, Life and Brain GmbH filed Critical Rheinische Friedrich Wilhelms Universitaet Bonn
Publication of CA2838945A1 publication Critical patent/CA2838945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2838945A 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use Abandoned CA2838945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15
US61/497,215 2011-06-15
PCT/EP2012/061485 WO2012172069A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Publications (1)

Publication Number Publication Date
CA2838945A1 true CA2838945A1 (en) 2012-12-20

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2838945A Abandoned CA2838945A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Country Status (13)

Country Link
US (1) US9573960B2 (zh)
EP (1) EP2721035B1 (zh)
JP (1) JP6228113B2 (zh)
CN (1) CN103764659A (zh)
AU (1) AU2012268984B2 (zh)
BR (1) BR112013032360A2 (zh)
CA (1) CA2838945A1 (zh)
CL (1) CL2013003563A1 (zh)
IL (1) IL229767A0 (zh)
MX (1) MX340816B (zh)
RU (1) RU2014101070A (zh)
WO (1) WO2012172069A1 (zh)
ZA (1) ZA201309365B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) * 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
WO2016210289A1 (en) 2015-06-24 2016-12-29 Duke University Chemical modulators of signaling pathways and therapeutic use
EP3328495A4 (en) * 2015-07-31 2019-01-16 Swedish Health Services METHODS AND COMPOSITIONS FOR CHARACTERIZING MULTIPLE-FORM GLIOBLASTOMA TUMORS AND CANCER STEM CELLS
US11499972B2 (en) 2015-09-15 2022-11-15 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
US11311606B2 (en) 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
WO2023183463A1 (en) * 2022-03-23 2023-09-28 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US6462041B1 (en) * 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
CN101289482B (zh) * 2007-09-29 2011-08-31 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Also Published As

Publication number Publication date
CN103764659A (zh) 2014-04-30
ZA201309365B (en) 2015-11-25
CL2013003563A1 (es) 2014-06-06
RU2014101070A (ru) 2015-07-20
US20150148390A1 (en) 2015-05-28
WO2012172069A1 (en) 2012-12-20
MX2013014708A (es) 2014-08-18
BR112013032360A2 (pt) 2017-06-13
EP2721035B1 (en) 2018-06-13
JP2014517025A (ja) 2014-07-17
AU2012268984B2 (en) 2016-07-14
EP2721035A1 (en) 2014-04-23
NZ618170A (en) 2015-04-24
MX340816B (es) 2016-07-26
JP6228113B2 (ja) 2017-11-08
US9573960B2 (en) 2017-02-21
IL229767A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
AU2012268984B2 (en) Glioblastoma inhibiting compounds and their use
AU2012268984A1 (en) Glioblastoma inhibiting compounds and their use
US9844522B2 (en) Niclosamide and its derivatives for use in the treatment of solid tumors
US8883749B2 (en) Transcription factor inhibitors and related compositions, formulations and methods
NO329994B1 (no) Deazapuriner, farmasoytiske preparater som omfatter forbindelsene og eventuelt et ytterligere terapeutisk middel, samt anvendelse av forbindelsene til tilvikning av et medikament for behandling av en inflammatorisk eller autoimmun lidelse eller proliferativ lidelse
UA120463C2 (uk) Похідні етинілу як модулятори метаботропного рецептора глутамату
WO2007101710A1 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2020253814A1 (zh) 一类雷公藤红素衍生物、其制备方法及用途
Byczek-Wyrostek et al. Simple 2 (5H)-furanone derivatives with selective cytotoxicity towards non-small cell lung cancer cell line A549–Synthesis, structure-activity relationship and biological evaluation
US10207998B2 (en) Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US20190358196A1 (en) Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant
CN112513000B (zh) 新型联苯衍生物化合物及其用途
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
NZ618170B2 (en) Glioblastoma inhibiting compounds and their use
EP2065039A1 (en) Selective inhibition of Polo-like kinase 1
Atapour-Mashhad et al. Synthesis and evaluation of cytotoxicity of 6-amino-4-aryl-2-thioxo-1, 2, 3, 4-tetrahydropyrimidine-5-carbonitriles
RU2809986C2 (ru) Новые производные феосферида, обладающие цитотоксической, противоопухолевой активностью и способностью преодолевать лекарственную устойчивость
KR101524770B1 (ko) 세포주기 조절을 통한 항암 효과를 보이는 폴리페놀
Gao et al. Peperomin E and its synthetic amino derivatives: potent agents targeting leukaemia stem cells
EP3381910B1 (en) 4-oxo-4,5-dihydrothiazole derivative, preparation method and use thereof
KR20230161639A (ko) 제주쑥 추출물을 함유하는 항암용 조성물
KR20220124128A (ko) 이엽우피소 에틸아세테이트 분획물을 유효성분으로 포함하는 항암용 조성물
KR20220162397A (ko) 뇌암의 예방 또는 치료용 조성물
JP2019218383A (ja) 癌及び心筋梗塞を治療する方法
JP2011207855A (ja) 抗がん剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170613

FZDE Discontinued

Effective date: 20200107